TY - JOUR
T1 - Whole-body protein turnover in metabolically stressed patients and patients with cancer as measured with [15N] glycine
AU - Stein, T. P.
AU - Ang, S. D.
AU - Schluter, M. D.
AU - Leskiw, M. J.
AU - Nusbaum, M.
PY - 1983/8
Y1 - 1983/8
N2 - The whole-body protein synthesis rate (PSR) was measured in 5 control patients (group I) and 38 patients in various clinical states (group II). A single pulse of [15N]glycine was given and the PSR calculated from the 15N enrichment in the urinary ammonia excreted over the next 10 hr. The patients' results fell into three separate groups: group IIa patients were nonstressed and had uneventful recoveries (3.1 ± 0.6 g prot./kg/day), their PSRs were the same as the control group I, (3.1 ± 1.0 g prot./kg/day); group IIb patients were stressed, had higher PSRs (6.3 ± 0.9 g prot./kg/day), one of whom died, and the rest had more complications than group IIa; group IIc patients had very high PSRs (15.4 ± 6.1 g prot./kg/day), all of whom were seriously ill, and 8 out 12 died; Data are ± 1 SD. The PSR correlated with the serum glutamate oxaloacetate transferase (SGOT, P < 0.01). We concluded: (i) [15N]glycine cannot be used to measure the PSR in patients with evidence of liver disease; the results are best interpreted in terms of glycine metabolism; (ii) the "apparent" PSR correlated with clinical status; and (iii) an elevated PSR in a patient with a malignancy is not necessarily due to protein metabolism by the tumor.
AB - The whole-body protein synthesis rate (PSR) was measured in 5 control patients (group I) and 38 patients in various clinical states (group II). A single pulse of [15N]glycine was given and the PSR calculated from the 15N enrichment in the urinary ammonia excreted over the next 10 hr. The patients' results fell into three separate groups: group IIa patients were nonstressed and had uneventful recoveries (3.1 ± 0.6 g prot./kg/day), their PSRs were the same as the control group I, (3.1 ± 1.0 g prot./kg/day); group IIb patients were stressed, had higher PSRs (6.3 ± 0.9 g prot./kg/day), one of whom died, and the rest had more complications than group IIa; group IIc patients had very high PSRs (15.4 ± 6.1 g prot./kg/day), all of whom were seriously ill, and 8 out 12 died; Data are ± 1 SD. The PSR correlated with the serum glutamate oxaloacetate transferase (SGOT, P < 0.01). We concluded: (i) [15N]glycine cannot be used to measure the PSR in patients with evidence of liver disease; the results are best interpreted in terms of glycine metabolism; (ii) the "apparent" PSR correlated with clinical status; and (iii) an elevated PSR in a patient with a malignancy is not necessarily due to protein metabolism by the tumor.
UR - http://www.scopus.com/inward/record.url?scp=0020562336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020562336&partnerID=8YFLogxK
U2 - 10.1016/0006-2944(83)90009-1
DO - 10.1016/0006-2944(83)90009-1
M3 - Article
C2 - 6626186
AN - SCOPUS:0020562336
SN - 0006-2944
VL - 30
SP - 59
EP - 77
JO - Biochemical medicine
JF - Biochemical medicine
IS - 1
ER -